EMILY MOORE: Open Payments
NPI 1538827209 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,235 in 49 payments from 8 companies in 2025. Trend: 2023 $96 · 2024 $375 · 2025 $1,235
Food & beverage: $1,235
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 18 | $430 |
| Neurocrine BioSciences, Inc. | 13 | $348 |
| Teva Pharmaceuticals USA, Inc. | 5 | $163 |
| Janssen Pharmaceuticals, Inc | 6 | $131 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $102 |
| E.R. Squibb & Sons, L.L.C. | 1 | $29 |
| ABBVIE INC. | 1 | $17 |
| Boston Scientific Corporation | 1 | $14 |
Products named: INGREZZA, ARISTADA, LYBALVI, UZEDY, CAPLYTA, INVEGA SUSTENNA, AUSTEDO XR, COBENFY.
Industry payments across TX — which companies pay providers there.
